Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

Detalles Bibliográficos
Autores principales: Tang, Guo-Qing, Tang, Yalan, Dhamnaskar, Ketki, Hoarty, Michelle D., Vyasamneni, Rohit, Vadysirisack, Douangsone D., Ma, Zhong, Zhu, Nanqun, Wang, Jian-Guo, Bu, Charlie, Cong, Bestine, Palmer, Elizabeth, Duda, Petra W., Sayegh, Camil, Ricardo, Alonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561601/
https://www.ncbi.nlm.nih.gov/pubmed/37818356
http://dx.doi.org/10.3389/fimmu.2023.1282155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561601/
https://www.ncbi.nlm.nih.gov/pubmed/37818356
http://dx.doi.org/10.3389/fimmu.2023.1282155

Ejemplares similares